John Morris

Dr. John Morris


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2019 in medRxiv
Verified
Preprint
Open access
PDF file
PLPamela J. LaMontagne
Pamela J. LaMontagne
TBTammie Benzinger
Tammie Benzinger
JMJohn Morris
John Morris
SKSarah Keefe
Sarah Keefe
RHRuss Hornbeck
Russ Hornbeck
DMDaniel Marcus
Daniel Marcus
OASIS-3 is a compilation of MRI and PET imaging and related clinical data for 1098 participants who were collected across several ongoing studies in the Washington University Knight Alzheimer Disease Research Center over the course of 15 years. Participants include 605 cognitively normal adults and 493 individuals at various stages of cognitive decline ranging in age from 42 to 95 years. The OASIS-3 dataset contains over 2000 MR sessions, including multiple structural and functional sequences. PET metabolic and amyloid imaging includes over 1500 raw imaging scans and the accompanying post-processed files from the PET Unified Pipeline (PUP) are also available in OASIS-3. OASIS-3 also contains post-processed imaging data such as volumetric segmentations and PET analyses. Imaging data is accompanied by dementia and APOE status and longitudinal clinical and cognitive outcomes. OASIS-3 is available as an open access data set to the scientific community to answer questions related to healthy aging and dementia.

1 March 2019 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
JMJohn Morris
John Morris
SSSuzanne E. Schindler
Suzanne E. Schindler
LMLena M. McCue
Lena M. McCue
KMKrista L. Moulder
Krista L. Moulder
TBTammie L. S. Benzinger
Tammie L. S. Benzinger
CXChengjie Xiong
Chengjie Xiong
Potential racial differences have been examined in Alzheimer disease (AD), particularly for African American individuals compared with non-Hispanic white individuals,1 but the evidence is often conflicting. For example, some studies suggest an increased incidence and prevalence for dementia and AD in African American individuals compared with non-Hispanic white individuals,2-4 but other studies find no racial differences in the risk for AD.5,6 There are similar discrepancies as to whether AD-related neuropathologic differences do7 or do not8,9 exist between African American and white individuals and whether there are racial differences in hippocampal volumes.10,11

9 August 2019 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
JDJorge Del-Aguila
Jorge Del-Aguila
ZLZeran Li
Zeran Li
UDUmber Dube
Umber Dube
KMKathie A. Mihindukulasuriya
Kathie A. Mihindukulasuriya
JBJohn P. Budde
John P. Budde
OHOscar Harari
Oscar Harari
Alzheimer’s disease (AD) is the most common form of dementia. This neurodegenerative disorder is associated with neuronal death and gliosis heavily impacting the cerebral cortex. AD has a substantial but heterogeneous genetic component, presenting both Mendelian and complex genetic architectures. Using bulk RNA-seq from the parietal lobes and deconvolution methods, we previously reported that brains exhibiting different AD genetic architecture exhibit different cellular proportions. Here, we sought to directly investigate AD brain changes in cell proportion and gene expression using single-cell resolution. We generated unsorted single-nuclei RNA sequencing data from brain tissue. We leveraged the tissue donated from a carrier of a Mendelian genetic mutation, PSEN1 p.A79V, and two family members who suffer from sporadic AD, but do not carry any autosomal mutations. We evaluated alternative alignment approaches to maximize the titer of reads, genes, and cells with high quality. In addition, we employed distinct clustering strategies to determine the best approach to identify cell clusters that reveal neuronal and glial cell types and avoid artifacts such as sample and batch effects. We propose an approach to cluster cells that reduces biases and enable further analyses. We identified distinct types of neurons, both excitatory and inhibitory, and glial cells, including astrocytes, oligodendrocytes, and microglia, among others. In particular, we identified a reduced proportion of excitatory neurons in the Mendelian mutation carrier, but a similar distribution of inhibitory neurons. Furthermore, we investigated whether single-nuclei RNA-seq from the human brains recapitulate the expression profile of disease-associated microglia (DAM) discovered in mouse models. We also determined that when analyzing human single-nuclei data, it is critical to control for biases introduced by donor-specific expression profiles. We propose a collection of best practices to generate a highly detailed molecular cell atlas of highly informative frozen tissue stored in brain banks. Importantly, we have developed a new web application to make this unique single-nuclei molecular atlas publicly available.

1 January 2019 in Neurobiology of Disease
Verified
Journal Article
Closed access
IBIsabel Barroeta-Espar
Isabel Barroeta-Espar
LWLaura D. Weinstock
Laura D. Weinstock
BPBeatriz G. Perez-Nievas
Beatriz G. Perez-Nievas
AMAvery C. Meltzer
Avery C. Meltzer
MCMichael Siao Tick Chong
Michael Siao Tick Chong
TGTeresa Gomez-Isla
Teresa Gomez-Isla

8 May 2019 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
JDJorge Del-Aguila
Jorge Del-Aguila
BBBruno A. Benitez
Bruno A. Benitez
ZLZeran Li
Zeran Li
UDUmber Dube
Umber Dube
KMKathie A. Mihindukulasuriya
Kathie A. Mihindukulasuriya
CCCarlos Cruchaga
Carlos Cruchaga
Low frequency coding variants in TREM2 are associated with Alzheimer disease (AD) risk and cerebrospinal fluid (CSF) TREM2 protein levels are different between AD cases and controls. Similarly, TREM2 risk variant carriers also exhibit differential CSF TREM2 levels. TREM2 has three different alternative transcripts, but most of the functional studies only model the longest transcript. No studies have analyzed TREM2 expression levels or alternative splicing in brains from AD and cognitively normal individuals. We wanted to determine whether there was differential expression of TREM2 in sporadic-AD cases versus AD-TREM2 carriers vs sex- and aged-matched normal controls; and if this differential expression was due to a particular TREM2 transcript. We analyzed RNA-Seq data from parietal lobe brain tissue from AD cases with TREM2 variants (n = 33), AD cases (n = 195) and healthy controls (n = 118), from three independent datasets using Kallisto and the R package tximport to determine the read count for each transcript and quantified transcript abundance as transcripts per million. The three TREM2 transcripts were expressed in brain cortex in the three datasets. We demonstrate for the first time that the transcript that lacks the transmembrane domain and encodes a soluble form of TREM2 (sTREM2) has an expression level around 60% of the canonical transcript, suggesting that around 25% of the sTREM2 protein levels could be explained by this transcript. We did not observe a difference in the overall TREM2 expression level between cases and controls. However, the isoform which lacks the 5′ exon, but includes the transmembrane domain, was significantly lower in TREM2- p.R62H carriers than in AD cases (p = 0.007). Using bulk RNA-Seq data from three different cohorts, we were able to quantify the expression level of the three TREM2 transcripts, demonstrating: (1) all three transcripts of them are highly expressed in the human cortex, (2) that up to 25% of the sTREM2 may be due to the expression of a specific isoform and not TREM2 cleavage; and (3) that TREM2 risk variants do not affect expression levels, suggesting that the effect of the TREM2 variants on CSF levels occurs at post-transcriptional level.

21 July 2021 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
EMEric McDade
Eric McDade
JLJorge J. Llibre-Guerra
Jorge J. Llibre-Guerra
DHDavid Holtzman
David Holtzman
JMJohn Morris
John Morris
RBRandall J. Bateman
Randall J. Bateman
Alzheimer disease (AD) prevention trials hold the promise to delay or prevent cognitive decline and dementia onset by intervening before significant neuronal damage occurs. In recent years, the first AD prevention trials have launched and are yielding important findings on the biology of targeting asymptomatic AD pathology. However, there are limitations that impact the design of these prevention trials, including the translation of animal models that recapitulate key stages and multiple pathological aspects of the human disease, missing target validation in asymptomatic disease, uncertain causality of the association of pathophysiologic changes with cognitive and clinical symptoms, and limited biomarker validation for novel targets. The field is accelerating advancements in key areas including the development of highly specific and quantitative biomarker measures for AD pathology, increasing our understanding of the course and relationship of amyloid and tau pathology in asymptomatic through symptomatic stages, and the development of powerful interventions that can slow or reverse AD amyloid pathology. We review the current status of prevention trials and propose key areas of needed research as a call to basic and translational scientists to accelerate AD prevention. Specifically, we review (1) sporadic and dominantly inherited primary and secondary AD prevention trials, (2) proposed targets, mechanisms, and drugs including the amyloid, tau, and inflammatory pathways and combination treatments, (3) the need for more appropriate prevention animal models and experiments, and (4) biomarkers and outcome measures needed to design human asymptomatic prevention trials. We conclude with actions needed to effectively move prevention targets and trials forward.